Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHA:688393)
China · Delayed Price · Currency is CNY 27.67
-0.09 (-0.32%)
At close: Feb 13, 2026
SHA:688393 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 365.04 | 464.8 | 490.94 | 504.62 | 437.44 | 374.57 |
Other Revenue | 5.99 | 5.99 | 6.35 | 2.76 | 1.55 | 0.87 |
| 371.03 | 470.79 | 497.29 | 507.38 | 438.99 | 375.43 | |
Revenue Growth (YoY) | -25.11% | -5.33% | -1.99% | 15.58% | 16.93% | 5.71% |
Cost of Revenue | 137.98 | 159.61 | 161.87 | 148.97 | 98.6 | 76.19 |
Gross Profit | 233.05 | 311.18 | 335.42 | 358.41 | 340.39 | 299.24 |
Selling, General & Admin | 224.22 | 262.83 | 258.79 | 260.14 | 232.02 | 185.72 |
Research & Development | 42.97 | 45.47 | 62.69 | 67.39 | 45.9 | 27.73 |
Other Operating Expenses | 2.08 | 1.78 | 1.9 | 4.04 | 1.97 | 1.88 |
Operating Expenses | 270.35 | 315.75 | 327.88 | 336.92 | 281.59 | 221.35 |
Operating Income | -37.3 | -4.56 | 7.54 | 21.49 | 58.8 | 77.89 |
Interest Expense | -0.51 | -0.65 | -0.81 | -1.36 | -0.38 | - |
Interest & Investment Income | 7.54 | 11.99 | 8.8 | 7.69 | 19.12 | 10.29 |
Earnings From Equity Investments | 0 | 0 | 0 | -0 | - | - |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | -0.08 | 0.14 | -0.06 | -0.1 |
Other Non Operating Income (Expenses) | 1.26 | -0.25 | -0.31 | -0.28 | -0.38 | -0.21 |
EBT Excluding Unusual Items | -29.01 | 6.52 | 15.14 | 27.68 | 77.09 | 87.87 |
Impairment of Goodwill | - | - | -3.06 | - | - | - |
Gain (Loss) on Sale of Investments | 3.53 | 2.53 | 5.14 | -3.14 | 6.12 | 0.46 |
Gain (Loss) on Sale of Assets | 0.1 | 0.16 | -0.64 | 0.15 | -0.61 | -0.55 |
Asset Writedown | -4.61 | -3.69 | - | - | - | - |
Other Unusual Items | 2.11 | 3.92 | 0.27 | 4.11 | 6.12 | 12.08 |
Pretax Income | -27.88 | 9.43 | 16.85 | 28.79 | 88.72 | 99.85 |
Income Tax Expense | -7.81 | -5.47 | -4.17 | -0.54 | 13.44 | 16.23 |
Earnings From Continuing Operations | -20.07 | 14.9 | 21.02 | 29.33 | 75.28 | 83.62 |
Minority Interest in Earnings | 0.96 | 6.39 | 19.04 | 13.36 | 4.49 | 1.12 |
Net Income | -19.11 | 21.29 | 40.06 | 42.69 | 79.78 | 84.75 |
Net Income to Common | -19.11 | 21.29 | 40.06 | 42.69 | 79.78 | 84.75 |
Net Income Growth | - | -46.85% | -6.18% | -46.48% | -5.87% | 14.54% |
Shares Outstanding (Basic) | 90 | 93 | 93 | 93 | 94 | 78 |
Shares Outstanding (Diluted) | 90 | 93 | 95 | 95 | 94 | 78 |
Shares Change (YoY) | -6.37% | -2.94% | 0.53% | 1.09% | 20.71% | 11.39% |
EPS (Basic) | -0.21 | 0.23 | 0.43 | 0.46 | 0.85 | 1.09 |
EPS (Diluted) | -0.21 | 0.23 | 0.42 | 0.45 | 0.85 | 1.09 |
EPS Growth | - | -45.24% | -6.67% | -47.06% | -22.02% | 2.83% |
Free Cash Flow | 22.41 | -20.1 | -20.62 | -62.45 | -83.73 | 28.98 |
Free Cash Flow Per Share | 0.25 | -0.22 | -0.22 | -0.66 | -0.89 | 0.37 |
Dividend Per Share | 0.100 | 0.100 | 0.150 | 0.140 | 0.270 | 0.280 |
Dividend Growth | -33.33% | -33.33% | 7.14% | -48.15% | -3.57% | - |
Gross Margin | 62.81% | 66.10% | 67.45% | 70.64% | 77.54% | 79.71% |
Operating Margin | -10.05% | -0.97% | 1.52% | 4.23% | 13.39% | 20.75% |
Profit Margin | -5.15% | 4.52% | 8.05% | 8.42% | 18.17% | 22.57% |
Free Cash Flow Margin | 6.04% | -4.27% | -4.15% | -12.31% | -19.07% | 7.72% |
EBITDA | 0.97 | 33.68 | 45.74 | 53.84 | 75.33 | 88.35 |
EBITDA Margin | 0.26% | 7.15% | 9.20% | 10.61% | 17.16% | 23.53% |
D&A For EBITDA | 38.27 | 38.24 | 38.2 | 32.35 | 16.53 | 10.46 |
EBIT | -37.3 | -4.56 | 7.54 | 21.49 | 58.8 | 77.89 |
EBIT Margin | -10.05% | -0.97% | 1.52% | 4.23% | 13.39% | 20.75% |
Effective Tax Rate | - | - | - | - | 15.15% | 16.25% |
Revenue as Reported | 371.03 | 470.79 | 497.29 | 507.38 | 438.99 | 375.43 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.